Goldman Sachs’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $27.7M | Buy |
911,976
+463,993
| +104% | +$12.4M | ﹤0.01% | 2130 |
|
|
2025
Q4 | $12.9M | Buy |
447,983
+272,341
| +155% | +$3.56M | ﹤0.01% | 2826 |
|
|
2025
Q3 | $1.27M | Buy |
175,642
+103,671
| +144% | +$763K | ﹤0.01% | 4868 |
|
|
2025
Q2 | $715K | Sell |
71,971
-339,170
| -82% | -$3.58M | ﹤0.01% | 4936 |
|
|
2025
Q1 | $3.9M | Buy |
411,141
+116,373
| +39% | +$1.62M | ﹤0.01% | 3596 |
|
|
2024
Q4 | $4.07M | Buy |
294,768
+216,504
| +277% | +$3.79M | ﹤0.01% | 3659 |
|
|
2024
Q3 | $1.19M | Sell |
78,264
-4,432
| -5% | -$21.9K | ﹤0.01% | 4526 |
|
|
2024
Q2 | $394K | Sell |
82,696
-130,473
| -61% | -$728K | ﹤0.01% | 4952 |
|
|
2024
Q1 | $1.45M | Buy |
213,169
+197,929
| +1,299% | +$957K | ﹤0.01% | 4092 |
|
|
2023
Q4 | $74.5K | Sell |
15,240
-9,309
| -38% | -$30.3K | ﹤0.01% | 5336 |
|
|
2023
Q3 | $84K | Hold |
24,549
| – | – | ﹤0.01% | 5208 |
|
|
2023
Q2 | $117K | Sell |
24,549
-75
| -0.3% | -$330 | ﹤0.01% | 5331 |
|
|
2023
Q1 | $104K | Buy |
24,624
+30
| +0.1% | +$129 | ﹤0.01% | 5455 |
|
|
2022
Q4 | $94.9K | Sell |
24,594
-370
| -1% | -$1.77K | ﹤0.01% | 5490 |
|
|
2022
Q3 | $150K | Buy |
24,964
+15
| +0.1% | +$77 | ﹤0.01% | 5576 |
|
|
2022
Q2 | $87K | Sell |
24,949
-17,289
| -41% | -$61.4K | ﹤0.01% | 5904 |
|
|
2022
Q1 | $145K | Buy |
42,238
+11,821
| +39% | +$46.6K | ﹤0.01% | 5987 |
|
|
2021
Q4 | $89K | Buy |
30,417
+8,279
| +37% | +$29K | ﹤0.01% | 6166 |
|
|
2021
Q3 | $89K | Buy |
+22,138
| New | +$101K | ﹤0.01% | 5934 |
|
|
2020
Q3 | – | Sell |
-38,808
| Closed | -$179K | – | 5322 |
|
|
2020
Q2 | $179K | Buy |
+38,808
| New | +$169K | ﹤0.01% | 4827 |
|
|
2017
Q3 | – | Sell |
-4,082
| Closed | -$34K | – | 6669 |
|
|
2017
Q2 | $34K | Sell |
4,082
-1,697
| -29% | -$31K | ﹤0.01% | 6451 |
|
|
2017
Q1 | $195K | Sell |
5,779
-1,777
| -24% | -$49.3K | ﹤0.01% | 5743 |
|
|
2016
Q4 | $201K | Sell |
7,556
-2,529
| -25% | -$75.7K | ﹤0.01% | 5768 |
|
|
2016
Q3 | $327K | Sell |
10,085
-475
| -4% | -$17.9K | ﹤0.01% | 5411 |
|
|
2016
Q2 | $417K | Sell |
10,560
-236
| -2% | -$8.33K | ﹤0.01% | 5028 |
|
|
2016
Q1 | $274K | Sell |
10,796
-478
| -4% | -$11.6K | ﹤0.01% | 5345 |
|
|
2015
Q4 | $347K | Sell |
11,274
-2,494
| -18% | -$99.2K | ﹤0.01% | 5231 |
|
|
2015
Q3 | $558K | Buy |
13,768
+7,342
| +114% | +$327K | ﹤0.01% | 5028 |
|
|
2015
Q2 | $325K | Buy |
+6,426
| New | +$403K | ﹤0.01% | 5652 |
|
Other funds holding CAPR
SCM
TCM
VCM
RCM
JHC
Goldman Sachs's CAPR Position: Q1 2026 in Review
Goldman Sachs increased its Capricor Therapeutics (CAPR) stake by 104% in Q1 2026, buying an estimated $12.4M and bringing the position to 911,976 shares worth $27.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2130.
Goldman Sachs first reported a position in CAPR in Q2 2015 and has held it in 29 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.
- Goldman Sachs held 911,976 shares of Capricor Therapeutics worth $27.7M as of Q1 2026.
- Goldman Sachs bought 463,993 Capricor Therapeutics shares in Q1 2026, an estimated $12.4M.
- Capricor Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2130 holding.
- Goldman Sachs first reported a position in Capricor Therapeutics in Q2 2015 and has held it in 29 quarters since.
- 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.